paper-with-me

홈 › Papers

PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with conditional generative models

2020-05-27 · Jannis Born, Matteo Manica, Joris Cadow, Greta Markert, Nil Adell Mill, Modestas Filipavicius, María Rodríguez Martínez

With the fast development of COVID-19 into a global pandemic, scientists around the globe are desperately searching for effective antiviral therapeutic agents. Bridging systems biology and drug discovery, we propose a deep learning framework for conditional de novo design of antiviral candidate drugs tailored against given protein targets. First, we train a multimodal ligand--protein binding affinity model on predicting affinities of antiviral compounds to target proteins and couple this model with pharmacological toxicity predictors. Exploiting this multi-objective as a reward function of a conditional molecular generator (consisting of two VAEs), we showcase a framework that navigates the chemical space toward regions with more antiviral molecules. Specifically, we explore a challenging setting of generating ligands against unseen protein targets by performing a leave-one-out-cross-validation on 41 SARS-CoV-2-related target proteins. Using deep RL, it is demonstrated that in 35 out of 41 cases, the generation is biased towards sampling more binding ligands, with an average increase of 83% comparing to an unbiased VAE. We present a case-study on a potential Envelope-protein inhibitor and perform a synthetic accessibility assessment of the best generated molecules is performed that resembles a viable roadmap towards a rapid in-vitro evaluation of potential SARS-CoV-2 inhibitors.

📄 PDF Abstract BibTeX arXiv:2005.13285

Code (1)

PaccMann/paccmann_sarscov2 공식 구현

Tasks

Drug Discovery

Methods 이 논문이 사용한 방법론

USD Coin Customer Service Number +1-833-534-1729 설명 없음

Similar Papers 제목 키워드 기반

Machine-Learning Driven Drug Repurposing for COVID-19

2020-06-25 · Semih Cantürk, Aman Singh, Patrick St-Amant, Jason Behrmann

The integration of machine learning methods into bioinformatics provides particular benefits in identifying how therapeutics effective in one context might have utility in an unknown clinical context or against a novel p…

BIG-bench Machine Learning

Docking study for Protein Nsp-12 of SARS-CoV with Betalains and Alfa-Bisabolol

2020-12-28 · Isaac Lucas-Gómez, Abelardo López-Fernández, Brenda Karen González-Pérez, M. Rivas-Castillo Andrea 외

The present Health Crisis tests the response of modern science and medicine to finding treatment for a new COVID-19 disease. The presentation on the world stage of antivirals such as remdesivir, obeys to the continuous i…

Viroinformatics-based investigation of SARS-CoV-2 core proteins for potential therapeutic targets

2020-09-27 · Lokesh Agrawal, Thanasis Poullikkas, Scott Eisenhower, Carlo Monsanto 외

Due to SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) being a novel virus, there are currently no known effective antiviral drugs capable of slowing its progress. To accelerate the discovery of potential dr…

Drug Discovery

Drug Repurposing to find Inhibitors of SARS-CoV-2 Main Protease

2020-06-26 · Emilio Angelina, Sebastian Andujar, Oscar Parravicini, Daniel Enriz 외

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Currently there is…

DCcov: Repositioning of Drugs and Drug Combinations for SARS-CoV-2 Infected Lung through Constraint-Based Modelling

2021-03-25 · Ali Kishk, Maria Pires Pacheco, Thomas Sauter

The 2019 coronavirus disease (COVID-19) became a worldwide pandemic with currently no effective antiviral drug except treatments for symptomatic therapy. Flux balance analysis is an efficient method to analyze metabolic …